EPISODE 02
Keli Walbert, Horizon Therapeutics
Mark speaks with Keli Walbert, executive vice president of Horizon Therapeutics, about commercializing new therapies. Keli talks about the importance of seeing patients as people and consumers and providing them with “support beyond medicine.” This involves deeply delving into the ways a disease affects a patient’s life, in some cases even conducting ethnographic research in the patient’s home. Keli also shares about the launch of Horizon Tepezza, a first-in-class novel monoclonal antibody for treating thyroid eye disease.
